NEW BRUNSWICK SCIENTIFIC CO., INC. ACQUIRES RS BIOTECH LABORATORY
                                EQUIPMENT LIMITED


EDISON,  NEW  JERSEY,  NOVEMBER  17,  2003-New  Brunswick  Scientific  Co., Inc.
(NASDAQ:  NBSC), today announced it has acquired RS Biotech Laboratory Equipment
Ltd.,  a designer and manufacturer of CO2 incubators.  Founded in 1991 and based
in  Irvine,  Scotland, RS Biotech's line of state-of-the-art incubators are sold
in  more  than 40 countries and have been utilized in numerous studies conducted
by  life  science  and  biotech  research  customers.

The  company's  annual  sales approximate $3 million and the acquisition will be
immediately  accretive  to  New  Brunswick  Scientific's earnings.  Although the
terms of the acquisition were not disclosed the purchase price consisted of cash
and  notes.

Malcolm  McNab,  Managing  Director and one of the founders of RS Biotech, said:
"RS  Biotech's  impressive range of Galaxy CO2 Incubators adds strength and fits
naturally into the New Brunswick Scientific product portfolio.  There is obvious
synergy  across  a  wide  range  of activities, and considerable advantage to be
gained  from  complementary strengths ultimately leading to benefits for all our
customers  and  associated  parties."

David  Freedman,  Chairman  and  Chief  Executive  Officer  of  New  Brunswick
Scientific,  stated:  "We  are  very pleased to have acquired RS Biotech, as its
Galaxy  CO2  Incubators  represent  a strong addition to our lines of biological
shakers,  ultra-low temperature freezers, fermentors and cell culture equipment.
Furthermore,  from  a  human  resources point of view, the quality and talent of
their  people  matches  well  with  our  dedicated  and  experienced  staff."

New  Brunswick  Scientific  Co., Inc. designs and manufactures a wide variety of
research  equipment and scientific instruments for the life sciences and holds a
minority  equity  position  in  Antyra  Inc.,  a  drug-lead-discovery operation.

This  press  release  includes  statements  that  may constitute forward-looking
statements  made pursuant to the Safe Harbor provision of the Private Securities
Litigation  Reform  Act  of  1995.  This  information  may  involve  risks  and
uncertainties  that  could  cause  actual  results to differ materially from the
forward-looking  statements. Although the Company believes that the expectations
reflected  in  such  forward-looking  statements  are  based  on  reasonable
assumptions,  such  statements are subject to risks and uncertainties that could
cause  actual  results  to  differ  materially  from  those  projected.  Further
information concerning risk factors is described in the Company's Securities and
Exchange  Commission  filings.